echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Don't miss the oncology journal Hot Talk Top1! Friendly people, super fast reception, from birth letter to clinical coverage!

    Don't miss the oncology journal Hot Talk Top1! Friendly people, super fast reception, from birth letter to clinical coverage!

    • Last Update: 2022-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Oncology journals are hotly talking about Top1, and Frontiers in Oncology is the only one
    .


    Introduction to the journal

     

    FRONT ONCOL is one of the medical journals of Frontiers, founded in 2011 and published or managed
    by Frontiers Media S.
    A.
    in Switzerland.

     

    The editor-in-chief is Professor Giuseppe Giaccone from the Meyer Cancer Center at Cornell University, a bigwig-level scholar
    who has collaborated on nearly 600 papers.

     

    Image source: https://loop.
    frontiersin.
    org/people/20317/overview

     

    Journal Website:

    _msthash="320195" _msttexthash="233207">Submission URL:

    _msthash="320197" _msttexthash="966706">Chinese Academy of Sciences Division

    *MedSci Journal Index: It is based on the comprehensive evaluation of Chinese scientific researchers (including medical clinical, basic, biological, chemical and other disciplines) to SCI journals, their familiarity, and the amount of submissions
    .

     

     

    Review speed: average 3.
    44 months


    Submission hit rate: 53.


    Chinese publication ratio: 66.


    Self-citation rate: 2.


    Number of articles in 2300 years (2022)

    *The above data are from the contributions of netizens, not the official website information, for reference only

     

    FRONT ONCOL receives professional articles on cancer, including cancer epidemiology, molecular mechanisms, diagnosis and imaging, personalized diagnosis and treatment, and novel treatment management strategies
    .


     

     

     

     

    From Netizen 3(Message time2021-09-22)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.